Compound ID | 48

Update compound information

SASPject3.1

Class: Antimicrobial peptide

Spectrum of activity: Gram-negative
Details of activity: SASPject™ PT3.1 is being developed against Pseudomonas aeruginosa
Propensity to select resistant mutants: Yes
Institute where first reported: Phico Therapeutics Ltd., UK
Year first mentioned: 2014
Highest developmental phase: Preclinical
Development status: Experimental
External links:
Citations:
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538823/
  • http://www.phicotx.co.uk/#products
    • Patent: US20140242032A1

    AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.